MEDICAL TRIBUNE CZ > Poctivá věda nám otevřela dveře k vlastním klinickým studiím
.....
Imunoterapie do léčby karcinomu prostaty už reálně vstoupila. První a zatím jediný přípravek pro protinádorovou buněčnou imunoterapii sipuleucel‑T je registrován právě v této indikaci. Prokázal prodloužení celkového přežití o více než čtyři měsíce. V Evropě není dostupný, ale v USA se etabloval poměrně úspěšně, přestože tato léčba stojí 90 000 dolarů. ....
Text Messaging Program Launched for Prostate Cancer Patients
Text Messaging Program Launched for Prostate Cancer Patients
Related articles
- Sanofi backs mobile service for cancer patients on chemo
- Mobile Commons, Sanofi US, and the Prostate Cancer Foundation Partner to Improve Patient Understanding with the New PROST8CARE™ Text Messaging Program
- High-Tech Prostate Cancer Treatments: A Cost Analysis
- Louisville CyberKnife Offers Prostate Cancer Patients Advanced Form of Radiation Therapy
Shorter ADT Appears to Be Best for High-Risk Prostate Cancer
Shorter ADT Appears to Be Best for High-Risk Prostate Cancer
The study involved high-risk men, defined as having at least 1 of the following risk factors: T3 to T4 disease, a prostate-specific antigen (PSA) level above 20 ng/mL, or a Gleason score above 7. All of the men had node-negative disease.
The study involved high-risk men, defined as having at least 1 of the following risk factors: T3 to T4 disease, a prostate-specific antigen (PSA) level above 20 ng/mL, or a Gleason score above 7. All of the men had node-negative disease.
Survival Data and More
The 630 study participants (average age, 71 years) were randomized to either 36 or 18 months of androgen-blockade therapy, consisting of bicalutamide 50 mg (a nonsteriodal antiandrogen) for 1 month and goserelin 10.8 mg (a luteinizing hormone-releasing hormone [LHRH]) every 3 months before, during, and after pelvic and prostate radiotherapy.
From October 2000 to January 2008, 310 patients were randomized to the 36-month group and 320 to the 18-month group. Most had T2 to T3 disease.
At 5 years, overall survival in the 36-month and 18-month treatment groups was comparable (92.1% vs 86.8%; P = .052); the same was true at 10 years (63.6% vs 63.2%; P = .429).
Similarly, at 5 years, disease-specific survival in the 36-month and 18-month treatment groups was comparable (97.6% vs 96.4%; P = .473); the same was true at 10 years (87.2% vs 87.2%; P = .838).
In addition, there were no significant differences between the 2 treatment groups for a host of other measures: biochemical failure, second course of androgen blockade therapy, pelvic node metastases, bone metastases, and causes of death.
At 77 months, 71 of 310 patients (22.9%) in the 36-month group and 76 of 320 (23.8%) in the 18-month group had died (P = .802).
The main causes of death for all patients were a second cancer (7.3%), prostate cancer (4.9%), and cardiovascular disease (4.4%). Age was the only risk factor that was statistically significant in the study. "Older patients die more rapidly," said Dr. Nabid.
The combination of bicalutamide and goserelin, which is a LHRH agonist, is a strategy known as androgen blockade, and is a somewhat controversial choice, Dr. Roth told Medscape Medical News in an interview. It is "almost universal" clinical practice to either use an LHRH agonist or remove the testicles to achieve castrate levels of testosterone. But the utility of adding an antiandrogen (in this case bicalutamide) is a matter of debate, he said.......
Related articles
Přihlásit se k odběru:
Příspěvky (Atom)
Nerve-Sparing During Robot-Assisted Radical Prostatectomy Increases the Risk of Ipsilateral Positive Surgical Margins
Soeterik TFW, van Melick HHE, Dijksman LM, Stomps S, Witjes JA, van Basten JPA. Nerve-Sparing During Robot-Assisted Radical Prostatectomy In...